Lona Poole

Learn More
INTRODUCTION The purpose of this analysis was to determine the potential efficacy of recombinant human tissue factor pathway inhibitor (tifacogin) in a subpopulation of patients with community-acquired pneumonia (CAP) from a phase III study of severe sepsis. METHODS A retrospective review of patients with suspected pneumonia was conducted by an(More)
BACKGROUND A substantial proportion of patients with gastro-oesophageal reflux disease (GERD) have only a partial response to proton pump inhibitor (PPI) therapy. Prokinetic drugs may improve reflux symptoms by enhancing oesophageal motility and gastric emptying. AIM To evaluate the effect of revexepride, a novel prokinetic 5-hydroxytryptamine type 4(More)
  • 1